Roberto Fournier, OD
NPI 1982127973 · Optometrist · El Paso, TX
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1982127973
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- OD
- Sex
- Male
- Sole proprietor
- Yes
- License
- 9228T (TX)
Specialties & taxonomies
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
8 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
484 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Complete Exam of Visual System92014 | 171 | $126 |
| Established Patient Problem Focused Exam of Visual System92012 | 108 | $89 |
| Photography of the Retina92250 | 83 | $37 |
| New Patient Complete Exam of Visual System92004 | 54 | $150 |
| Imaging of Optic Nerve92133 | 37 | $36 |
| Imaging of Retina92134 | 17 | $41 |
| Ultrasound Scan of Cornea to Determine Thickness76514 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 29 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 1,290 | 308 |
| Lifitegrastbrand: Xiidra | 269 | 99 |
| Latanoprostene Bunodbrand: Vyzulta | 261 | 76 |
| Cyclosporinebrand: Restasis | 217 | 80 |
| Bimatoprostbrand: Lumigan | 171 | 46 |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 167 | 40 |
| Timolol Maleate | 141 | 44 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$718 across 24 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2017-07-21
- Last updated
- 2017-07-21
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.